Lv11
20 积分 2024-05-19 加入
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States
3小时前
已完结
CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma
15天前
已完结
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia
1个月前
已关闭
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
1个月前
已完结
Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis
1个月前
已完结
Fratricide-resistant CD7-CAR T cells in T-ALL
1个月前
已完结
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma
1个月前
已完结
Emerging drug profile: JAK inhibitors
2个月前
已完结
Therapeutic Inhibition of the JAK-STAT pathway in the treatment of Inflammatory Bowel Disease
2个月前
已完结
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
3个月前
已完结
皖公网安备34019202002308
